bisphosphonates - malecare.org

How Long Is It Safe to Take Bisphosphonates for Osteoporosis? Long Term Bisphosphonate Therapy Increases the Risk for Serious Fractures of the Femur

A John’s Hopkins Health Alert titled “How Long Is It Safe to Take Bisphosphonates for Osteoporosis?” Should Raise Some Concerns Men on Long Term Bisphosphonate Therapy Hormone therapy (ADT) is notorious for many negative side effects, including osteoporosis. Osteoporosis is the thinning of bone that increases the risk for fractures, especially hip and spine fractures. [...]

By Malecare|2020-02-04T11:27:24-05:00January 27th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Mineral Density, denosumab - Xgeva, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC, Xgeva|0 Comments

Zoledronic Acid (ZA) in Castrate Sensitive Prostate Cancer Does Not Prove To Be Advantageous

One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]

By Malecare|2017-10-19T10:49:08-04:00December 17th, 2013|Advanced Prostate Cancer, ASCO, bisphosphonates, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Uncategorized, Understanding APC, Zometa|1 Comment

Bone Disease in Men with Prostate Cancer Needs Constant Monitoring

The number of cancer survivors is increasing, soon to be as many of 13 million of us in the world! Bones are often affected in cancer survivors, usually a result of bone metastases, or of anti-cancer therapies which can contribute to bone loss and fragility. Bone disease in cancer survivors can result both from the [...]

By Malecare|2013-11-04T20:25:00-05:00November 4th, 2013|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, Bone Mineral Density, denosumab - Xgeva, Drugs & Treatments, General Information, Hormone Therapy, Quality of Life, Uncategorized, Understanding APC, Zometa|0 Comments

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

By Malecare|2020-02-04T11:49:50-05:00September 4th, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, biomarkers, bisphosphonates, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Hormone Therapy, Research, Start A Cure, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Study Shows that the Metastasis-Free Period Affects Prostate Cancer Patient Survival

A study from Michael T. Schweizer, MD, and colleagues at Johns Hopkins University in Baltimore Md. concluded that the longer the metastasis-free survival after a radical prostatectomy the longer overall survival in men who experience biochemical recurrence (PSA only recurrence) of their prostate cancer. This conclusion was made from a retrospectively study of 450 men [...]

By Malecare|2013-08-22T09:22:44-04:00August 22nd, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, bisphosphonates, denosumab - Xgeva, General Information, Metastases, Research, Uncategorized, Understanding APC|0 Comments